Kairos Pharma (KAPA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 May, 2026Executive summary
The 2026 Annual Meeting of Stockholders is scheduled for June 29, 2026, and will be held virtually, allowing online participation by shareholders.
The proxy statement was supplemented to correct the record date for voting eligibility to May 18, 2026.
Voting matters and shareholder proposals
Only shareholders of record as of May 18, 2026, are entitled to vote at the 2026 Annual Meeting and any adjournments.
The meeting agenda and proposals are detailed in the proxy statement and its supplement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kairos Pharma
- ENV105 targets CD105 to reverse cancer drug resistance, with pivotal trial data expected by 2027.KAPA
H.C. Wainwright 28th Annual Global Investment Conference - ENV105 leads a robust pipeline targeting cancer resistance, with strong early clinical results and funding.KAPAInvestor presentation
- Net loss increased, cash declined, and continued operations depend on securing new funding.KAPAQ2 2026
- Lead antibody ENV105 targets drug resistance in cancer, with key trial readouts expected soon.KAPAMaxim Group’s 2024 Healthcare Virtual Summit
- All proposals, including director elections and equity plan amendments, were approved by stockholders.KAPAAGM 2026
- Virtual meeting to vote on directors, auditor, reverse split, and expanded equity plan.KAPAProxy filing
- Advancing drug resistance therapies with major 2026 clinical and partnership milestones ahead.KAPA16th Annual LD Micro Invitational Conference
- ENV105 and KROS 741 advance in trials to address cancer resistance, backed by strong funding.KAPAInvestor presentation
- Q1 2026 net loss widened to $1.65M, cash at $3.68M, with new financing and manufacturing deals.KAPAQ1 2026